Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Windtree Therapeutics ( (WINT) ) has issued an announcement.
On June 27 and July 2, 2025, Windtree Therapeutics entered into note purchase agreements with several purchasers, issuing Convertible Promissory Notes totaling $253,333 to fund operational expenses, including a loan to Titan Environmental Services, Inc. The notes, convertible to common stock, accrue 14% interest annually and include warrants for additional stock purchases, reflecting strategic financial maneuvers to support company operations.
The most recent analyst rating on (WINT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Windtree Therapeutics stock, see the WINT Stock Forecast page.
Spark’s Take on WINT Stock
According to Spark, TipRanks’ AI Analyst, WINT is a Underperform.
Windtree Therapeutics faces significant financial challenges with no revenue and considerable net losses, severely impacting its financial health and stability in the biotechnology sector. The technical analysis suggests bearish momentum, aligning with the weak financials. The negative P/E ratio and lack of dividends make valuation unattractive. Recent corporate events provide a minor positive outlook, but overall, the stock presents considerable risks with limited upside potential without a substantial change in financial performance or market conditions.
To see Spark’s full report on WINT stock, click here.
More about Windtree Therapeutics
Windtree Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapies for acute cardiovascular and pulmonary conditions.
Average Trading Volume: 3,863,799
Technical Sentiment Signal: Sell
Current Market Cap: $2.01M
Learn more about WINT stock on TipRanks’ Stock Analysis page.